All news from Venereology

Multidrug-Resistant HIV-1: Ibalizumab Reduces the Viral Load

Ibalizumab significantly reduces viral load in patients with multidrug-resistant (MDR) HIV-1, according to results from a single-arm, open-label phase 3 study. "Ibalizumab will provide an additional opportunity to achieve viral suppression for patients who have exhausted most currently available treatment options," Dr. Stanley Lewis from TaiMed Biologics, in Irvine, California reported.

HIV Self-testing via Text Message to Sex Workers in Kenya Promoted, Study

Across the globe, HIV prevalence among sex workers is estimated to be as much as 12 times that of the general population. In Kenya, HIV prevalence among sex workers is about 30% compared to 5.4% in the general population.

A number of studies have found that bringing HIV self-testing to potential users can increase HIV testing rates among key populations such as sex workers.

Under 21 Years Wmen Benefited with Catch-up HPV Vaccination

Girls and young women who initiate the human papillomavirus (HPV) vaccine series between ages 15 and 20 years and receive all three doses are adequately protected against cancers caused by HPV infection, new data suggest. Catch-up vaccination among those ages 21 to 26 does not provide the same benefit, however.

Potential New Drug Targets in the Fight Against HIV Uncovered

Johns Hopkins scientists report they have identified two potential new drug targets for the treatment of HIV. The finding is from results of a small, preliminary study of 19 people infected with both HIV—the virus that causes AIDS—and the hepatitis C virus.

The study revealed that two genes—CMPK2 and BCLG, are selectively activated in the presence of type 1 interferon, a drug once used as the first line of treatment against hepatitis C. Results of the study were published online in Science Advances.

Early Initiation Of Antiretroviral Therapy Benefits HIV-Infected Children

Without treatment, an HIV-infected child is at greater risk of disease progression to AIDS than an adult. Initiation of early treatment in infants shows an undeniable clinical benefit by reducing the risk of death in early childhood. It may also be accompanied by a significant reduction of the viral reservoir (the amount of total viral DNA present in the immune cells of patients), which could promote the accumulation of conditions required for remission.

New Approaches to Tackle Growing Threat of Untreatable Gonorrhea

Good news in the battle against the growing threat of drug-resistant “super gonorrhea”: Researchers at the University of Virginia School of Medicine and their collaborators in the United Kingdom have discovered a new way that the bacteria that cause gonorrhea resist the body’s immune defenses. Scientists can use this knowledge to develop vaccines or empower our immune system to take down a sexually transmitted bug that has already conquered most antibiotics.

HIV-infected Infants: Initiation of Early Treatment has Undeniable Benefits

The initial findings of the ANRS CLEAC study coordinated by Pierre Frange (Hôpital Necker – AP-HP), help define the immunological and virological benefits of early antiretroviral therapy in HIV-infected children living in France.

The results of this study will be presented by Florence Buseyne (Oncogenic Virus Epidemiology & Pathophysiology Team – Institut Pasteur) this Wednesday, 25 July at the 22nd International AIDS Conference (AIDS 2018) being held in Amsterdam from 23 to 26 July 2018.